Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system.

PubWeight™: 1.39^‹?› | Rank: Top 5%

🔗 View Article (PMID 27058680)

Published in Pain on May 01, 2016

Author Affiliations

1: aDepartment of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA bDepartment of Rehabilitation Medicine, University of Washington, Seattle, WA, USA cInstitute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA dSchool of Professional Psychology, Pacific University, Hillsboro, OR, USA eDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA fDepartment of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA gDepartment of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, USA hEvidera, Seattle, WA, USA iLORA Group, LLC, Royal Oak, MD, USA jUniversity of Maryland, Baltimore, MD, USA kDepartment of Pediatrics, Dalhousie University, Halifax, NS, Canada lDepartment of Psychology and Neuroscience, Dalhousie University, Halifax, NS, Canada mCentre for Pediatric Pain Research, IWK Health Center, Halifax, NS, Canada nPalm Beach Gardens, FL, USA oAmerican Chronic Pain Association, Rocklin, CA, USA pDesjardins Associates, Maplewood, NJ, USA qJohnson & Johnson, Titusville, NJ, USA rDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA sDepartment of Anesthesia, University of Pennsylvania, Philadelphia, PA, USA tDepartment of Neurology, University of Pennsylvania, Philadelphia, PA, USA uDepartment of Anesthesiology & Perioperative Medicine, Queen's University, Kingston, ON, Canada vDepartment of Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada wJazz Pharmaceuticals, Palo Alto, CA, USA xPurdue Pharma L.P., Stamford, CT, USA yVA Connecticut Healthcare System, West Haven, CT, USA zDepartment of Psychiatry, Yale University, New Haven, CT, USA aaDepartment of Neurology, Yale University, New Haven, CT, USA bbDepartment of Psychology, Yale University, New Haven, CT, USA ccCollegium Pharmaceutical,

Articles citing this ↘

Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov (2017) 0.77

Bias and reliability in pain ratings. Pain (2016) 0.75

[What does pain intensity mean from the patient perspective? : A qualitative study on the patient perspective of pain intensity as an outcome parameter in treatment evaluation and on the interpretability of pain intensity measurements]. Schmerz (2017) 0.75

Articles by these authors ⇆

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 11.80

The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol (2010) 10.65

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89

The Reactome pathway knowledgebase. Nucleic Acids Res (2013) 8.56

Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol (2006) 8.15

Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain (2007) 6.98

The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92

The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013. Nucleic Acids Res (2012) 6.90

Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28

Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med (2007) 5.68

Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40

Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain (2004) 5.12

The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull (2007) 5.09

Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain (2008) 4.59

Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36

Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28

Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol (2003) 4.27

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain (2003) 4.24

Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys (2009) 4.23

HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20

American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc (2010) 3.92

Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol (2003) 3.80

An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord (2007) 3.71

Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. Value Health (2011) 3.63

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum (2008) 3.62

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum (2006) 3.60

Meta-analysis of psychological interventions for chronic low back pain. Health Psychol (2007) 3.51

The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain (2010) 3.51

The epidemiology of chronic pain in children and adolescents revisited: a systematic review. Pain (2011) 3.49

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol (2003) 3.47

Use of anesthetic agents in neonates and young children. Anesth Analg (2007) 3.46

Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. Value Health (2011) 3.45

MetaboLights--an open-access general-purpose repository for metabolomics studies and associated meta-data. Nucleic Acids Res (2012) 3.32

OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials (2007) 3.29

Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med (2002) 3.20

The future of general internal medicine. Report and recommendations from the Society of General Internal Medicine (SGIM) Task Force on the Domain of General Internal Medicine. J Gen Intern Med (2004) 3.19

Attempted suicide among transgender persons: The influence of gender-based discrimination and victimization. J Homosex (2006) 3.16

Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health (2007) 3.16

Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10

Natural genetic variation in lycopene epsilon cyclase tapped for maize biofortification. Science (2008) 3.06

Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet (2008) 3.06

Validity of four pain intensity rating scales. Pain (2011) 3.04

Social environment moderates the association between catastrophizing and pain among persons with a spinal cord injury. Pain (2003) 2.97

Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91

Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain (2010) 2.90

The anthropocene: from global change to planetary stewardship. Ambio (2011) 2.88

Neighborhood context and mortality among older Mexican Americans: is there a barrio advantage? Am J Public Health (2004) 2.87

Development of a PROMIS item bank to measure pain interference. Pain (2010) 2.85

Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81

Interventional management of neuropathic pain: NeuPSIG recommendations. Pain (2013) 2.75

The role of fear of movement in subacute whiplash-associated disorders grades I and II. Pain (2012) 2.72

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 2.71

Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials (2004) 2.66

Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest (2003) 2.60

An appraisal of William Thomas Green Morton's life as a narcissistic personality. Anesthesiology (2012) 2.60

Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys (2005) 2.58

Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain (2013) 2.58

Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58

p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54

Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain (2009) 2.53

American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med (2005) 2.52

Diagnostic tests: another frontier for less is more: or why talking to your patient is a safe and effective method of reassurance. Arch Intern Med (2010) 2.49

Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain (2009) 2.49